Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3034.00
ECTE's Cash to Debt is ranked higher than
81% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. ECTE: 3034.00 )
ECTE' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 3034

Equity to Asset 0.81
ECTE's Equity to Asset is ranked higher than
85% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. ECTE: 0.81 )
ECTE' s 10-Year Equity to Asset Range
Min: 0.15   Max: 0.94
Current: 0.81

0.15
0.94
F-Score: 2
Z-Score: -4.84
M-Score: -11.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -300800.00
ECTE's Operating margin (%) is ranked lower than
61% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. ECTE: -300800.00 )
ECTE' s 10-Year Operating margin (%) Range
Min: -300800   Max: 11.11
Current: -300800

-300800
11.11
Net-margin (%) -246640.00
ECTE's Net-margin (%) is ranked lower than
61% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. ECTE: -246640.00 )
ECTE' s 10-Year Net-margin (%) Range
Min: -246640   Max: -1.41
Current: -246640

-246640
-1.41
ROE (%) -120.54
ECTE's ROE (%) is ranked lower than
58% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. ECTE: -120.54 )
ECTE' s 10-Year ROE (%) Range
Min: -1146.14   Max: 1.92
Current: -120.54

-1146.14
1.92
ROA (%) -61.59
ECTE's ROA (%) is ranked lower than
57% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.95 vs. ECTE: -61.59 )
ECTE' s 10-Year ROA (%) Range
Min: -663.48   Max: 0.84
Current: -61.59

-663.48
0.84
ROC (Joel Greenblatt) (%) -918.19
ECTE's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.63 vs. ECTE: -918.19 )
ECTE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11468.75   Max: 25
Current: -918.19

-11468.75
25
Revenue Growth (%) -100.00
ECTE's Revenue Growth (%) is ranked lower than
60% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. ECTE: -100.00 )
ECTE' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 44.2
Current: -100

0
44.2
EBITDA Growth (%) 13.20
ECTE's EBITDA Growth (%) is ranked higher than
78% of the 504 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. ECTE: 13.20 )
ECTE' s 10-Year EBITDA Growth (%) Range
Min: -53.4   Max: 13.2
Current: 13.2

-53.4
13.2
EPS Growth (%) -19.90
ECTE's EPS Growth (%) is ranked higher than
57% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. ECTE: -19.90 )
ECTE' s 10-Year EPS Growth (%) Range
Min: -49.2   Max: 1644.6
Current: -19.9

-49.2
1644.6
» ECTE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2012

ECTE Guru Trades in Q2 2012

Jim Simons Sold Out
» More
Q2 2013

ECTE Guru Trades in Q2 2013

Jim Simons 56,607 sh (New)
» More
Q3 2013

ECTE Guru Trades in Q3 2013

Jim Simons 123,587 sh (+118.32%)
» More
Q4 2013

ECTE Guru Trades in Q4 2013

Jim Simons 115,287 sh (-6.72%)
» More
» Details

Insider Trades

Latest Guru Trades with ECTE



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.90
ECTE's P/B is ranked higher than
75% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. ECTE: 1.90 )
ECTE' s 10-Year P/B Range
Min: 0.45   Max: 30.39
Current: 1.9

0.45
30.39
P/S 909.10
ECTE's P/S is ranked lower than
93% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. ECTE: 909.10 )
ECTE' s 10-Year P/S Range
Min: 0   Max: 2622.22
Current: 909.1

0
2622.22
EV-to-EBIT 1000.00
ECTE's EV-to-EBIT is ranked lower than
79% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. ECTE: 1000.00 )
ECTE' s 10-Year EV-to-EBIT Range
Min: 0.8   Max: 37.8
Current: 1000

0.8
37.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.20
ECTE's Price/Net Cash is ranked lower than
65% of the 219 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.70 vs. ECTE: 18.20 )
ECTE' s 10-Year Price/Net Cash Range
Min: 1.02   Max: 307.69
Current: 18.2

1.02
307.69
Price/Net Current Asset Value 18.20
ECTE's Price/Net Current Asset Value is ranked lower than
69% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.80 vs. ECTE: 18.20 )
ECTE' s 10-Year Price/Net Current Asset Value Range
Min: 0.9   Max: 250
Current: 18.2

0.9
250
Price/Tangible Book 4.10
ECTE's Price/Tangible Book is ranked higher than
54% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. ECTE: 4.10 )
ECTE' s 10-Year Price/Tangible Book Range
Min: 0.42   Max: 451.11
Current: 4.1

0.42
451.11
Price/Median PS Value 2.30
ECTE's Price/Median PS Value is ranked lower than
64% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. ECTE: 2.30 )
ECTE' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 18.91
Current: 2.3

0.01
18.91
Earnings Yield (Greenblatt) 0.10
ECTE's Earnings Yield (Greenblatt) is ranked lower than
70% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. ECTE: 0.10 )
ECTE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 130.4
Current: 0.1

0.1
130.4
Forward Rate of Return (Yacktman) -50.16
ECTE's Forward Rate of Return (Yacktman) is ranked lower than
55% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. ECTE: -50.16 )
ECTE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -102.4   Max: -69.2
Current: -50.16

-102.4
-69.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:XS5B.Germany
Echo Therapeutics, Inc., is a transdermal medical device company with advanced skin permeation technology. The Company is developing its Symphony CGM System ('Symphony') as a non-invasive, wireless continuous glucose monitoring ('CGM') system for use in hospital critical care units and for people with diabetes. The Prelude SkinPrep System ('Prelude'), a component of Symphony CGM System, allows for enhanced skin permeation that enables extraction of analytes such as glucose. Prelude's platform skin preparation technology also allows for needle-free, transdermal drug delivery. Additional applications for needle-free analyte extraction and topical and systemic drug delivery are also planned. It is developing Prelude as a safe, effective, easy-to-use and low-cost transdermal skin preparation device for Symphony to enhance the access to the interstitial fluids and enhance the flow of molecules across the protective membrane of the stratum corneum, the outmost protective layer of the skin. The Company own or have rights to various copyrights, trademarks and trade names used in its business, including the following: Symphony tCGM System, Prelude SkinPrep System, AzoneTS and Durhalieve. The markets for glucose monitoring and drug delivery devices are particularly competitive, subject to rapid change and are affected by new product introductions and other market activities of industry participants. In the United States, pharmaceuticals, biologics and medical devices are subject to rigorous FDA regulation.
» More Articles for ECTE

Headlines

Articles On GuruFocus.com
5 Healthcare Picks for 2012 Mar 21 2012 

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide